AVN 101
Alternative Names: AVN-101; CD 008 0045Latest Information Update: 27 Sep 2022
Price :
$50 *
At a glance
- Originator ChemDiv
- Developer AllaChem; Avineuro Pharmaceuticals; ChemDiv
- Class Antidementias; Indoles; Neuroprotectants; Pyridines; Small molecules
- Mechanism of Action Adrenergic receptor antagonists; Dopamine receptor antagonists; Histamine receptor antagonists; Serotonin 6 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Alzheimer's disease; Anxiety disorders
Most Recent Events
- 27 Sep 2022 No development reported - Phase-II for Anxiety disorders in Russia (PO)
- 22 Dec 2020 Chemical structure information added
- 22 Oct 2020 Avineuro Pharmaceuticals and Avineuro Pharmaceuticals plans a phase III trial in Anxiety disorders in December 2020 (PO, Capsules) (NCT04598867)